new hepatitis c drugs sold in france fr 22,000

What does this make Biotron worth!

New hepatitis C drugs from Merck & Co. and Johnson & Johnson (JNJ) are being sold in France for 22,000 euros ($31,271) and more, a precedent some doctors say may limit access after the medicines are approved throughout Europe.

J&J and Vertex Pharmaceuticals Inc. (VRTX)?s telaprevir costs 22,000 euros under a French program for seriously ill patients for whom there is no other effective treatment on the market, according to patient association SOS Hepatites. Merck & Co. said its boceprevir costs 30,000 euros under the same program.

Merck, J&J?s New Hepatitis C Treatment Fetches $31,000 in France
By Naomi Kresge and Carol Matlack - Apr 5, 2011 6:15 AM GMT+1000 Bloomberg 6/april 2011